Generate Biomedicines Q3 net loss widens 46% year over year to $87.7 million; Q3 revenue falls 56% year over year to $4.2 million
- Generate Biomedicines’ third-quarter 2026 net loss widened 46% year-over-year to $87.7 million; revenue fell 56% to $4.2 million.
- Research and development expenses rose 32% year-over-year to $82.3 million, primarily driven by investment in GB-0895 Phase 3 severe asthma trials.
- Cash, cash equivalents and marketable securities totaled $404.2 million at Sept. 30; projected funding runway extends into the first half of 2028.
- The Zealand Pharma collaboration delivered $30 million upfront in October, with nearly $1.2 billion in potential milestones for obesity and metabolic-disease programs.
- GB-0895 remains in two Phase 3 severe asthma studies evaluating twice-yearly dosing; COPD findings showed sustained pharmacological activity for at least six months.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Generate Biomedicines Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-456921), on November 12, 2026, and is solely responsible for the information contained therein.